SMP201100024B - Composti che espandono cellule staminali ematopoietiche - Google Patents

Composti che espandono cellule staminali ematopoietiche

Info

Publication number
SMP201100024B
SMP201100024B SM201100024T SM201100024T SMP201100024B SM P201100024 B SMP201100024 B SM P201100024B SM 201100024 T SM201100024 T SM 201100024T SM 201100024 T SM201100024 T SM 201100024T SM P201100024 B SMP201100024 B SM P201100024B
Authority
SM
San Marino
Prior art keywords
compounds
stem cells
hematopoietic stem
expand hematopoietic
expand
Prior art date
Application number
SM201100024T
Other languages
English (en)
Other versions
SMAP201100024A (it
Inventor
Yongqin Wan
Shifeng Pan
Xing Wang
Anthony Boitano
Michael Cooke
Peter G Schultz
John TELLEW
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42111339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMP201100024(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of SMAP201100024A publication Critical patent/SMAP201100024A/it
Publication of SMP201100024B publication Critical patent/SMP201100024B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SM201100024T 2008-10-30 2011-05-13 Composti che espandono cellule staminali ematopoietiche SMP201100024B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10982108P 2008-10-30 2008-10-30
US24276509P 2009-09-15 2009-09-15
PCT/US2009/062646 WO2010059401A2 (en) 2008-10-30 2009-10-29 Compounds that expand hematopoietic stem cells

Publications (2)

Publication Number Publication Date
SMAP201100024A SMAP201100024A (it) 2011-07-11
SMP201100024B true SMP201100024B (it) 2012-03-05

Family

ID=42111339

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201100024T SMP201100024B (it) 2008-10-30 2011-05-13 Composti che espandono cellule staminali ematopoietiche

Country Status (41)

Country Link
US (4) US8927281B2 (it)
EP (2) EP2350078B1 (it)
JP (1) JP5390626B2 (it)
KR (1) KR101434719B1 (it)
CN (1) CN102203096B (it)
AR (1) AR074063A1 (it)
AU (1) AU2009317898B2 (it)
BR (1) BRPI0921799B8 (it)
CA (3) CA3061937A1 (it)
CL (2) CL2009002010A1 (it)
CO (1) CO6410309A2 (it)
CR (1) CR20110192A (it)
CU (1) CU24495B1 (it)
CY (1) CY1121857T1 (it)
DK (1) DK2350078T3 (it)
DO (1) DOP2011000114A (it)
EA (1) EA019872B1 (it)
EC (1) ECSP11011090A (it)
ES (2) ES2736728T3 (it)
GE (1) GEP20146053B (it)
HN (1) HN2011001195A (it)
HR (1) HRP20191238T1 (it)
HU (1) HUE044802T2 (it)
IL (1) IL212368A (it)
JO (1) JO3593B1 (it)
LT (1) LT2350078T (it)
MA (1) MA32828B1 (it)
MX (1) MX347834B (it)
MY (1) MY155137A (it)
NI (1) NI201100083A (it)
NZ (1) NZ592435A (it)
PE (1) PE20100362A1 (it)
PL (1) PL2350078T3 (it)
PT (1) PT2350078T (it)
RS (1) RS59027B1 (it)
SI (1) SI2350078T1 (it)
SM (1) SMP201100024B (it)
SV (1) SV2011003888A (it)
TN (1) TN2011000174A1 (it)
TW (1) TWI532486B (it)
WO (1) WO2010059401A2 (it)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846393B2 (en) * 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US20100105705A1 (en) * 2007-03-28 2010-04-29 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
WO2008116911A1 (en) * 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
WO2009146406A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
WO2010034707A1 (en) * 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
EP2344501A1 (en) * 2008-09-26 2011-07-20 NeuroSearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2012074068A1 (ja) 2010-12-01 2012-06-07 日産化学工業株式会社 ピラゾール化合物による造血幹細胞の製造方法
WO2012102937A2 (en) * 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
EP2713737B1 (en) 2011-06-01 2016-04-20 Janus Biotherapeutics, Inc. Novel immune system modulators
EP2729560A4 (en) * 2011-07-06 2014-12-03 Cellerant Therapeutics Inc MEGAKARYOCYTE PRE-PROVIDER CELLS FOR THE PRODUCTION OF BLOOD PLATES
US20140328811A1 (en) * 2011-08-01 2014-11-06 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
WO2013034685A1 (en) * 2011-09-07 2013-03-14 Deutsches Krebsforschungszentrum Means and methods for treating and/or preventing natural ahr ligand-dependent cancer
HK1203081A1 (en) * 2011-12-08 2015-10-16 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
PL2807165T3 (pl) 2012-01-27 2019-09-30 Université de Montréal Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych
WO2013121426A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
WO2014001282A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US9567569B2 (en) * 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
US9956249B2 (en) 2013-01-08 2018-05-01 Fred Hutchinson Cancer Research Center Compositions and methods for expansion of embryonic hematopoietic stem cells
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
CA2848575C (en) * 2013-05-17 2021-01-26 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
KR20160075676A (ko) * 2013-10-24 2016-06-29 오스페달레 산 라파엘 에스.알.엘. 방법
AU2014342020C1 (en) 2013-10-31 2019-09-05 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2016118780A1 (en) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
JP6985934B2 (ja) 2015-04-29 2021-12-22 フレッド ハッチンソン キャンサー リサーチ センター 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
BR112018007538A2 (pt) * 2015-10-15 2018-10-23 Celularity Inc células exterminadoras naturais e células ilc3 e usos das mesmas
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
AU2016343682A1 (en) 2015-10-30 2018-06-14 The Regents Of The University Of California Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
NZ783532A (en) 2015-12-28 2025-09-26 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
CN109121413A (zh) 2016-04-14 2019-01-01 弗莱德哈钦森癌症研究中心 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法
SG11201809858RA (en) * 2016-05-07 2018-12-28 Celularity Inc Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
MX2018014443A (es) 2016-05-25 2019-04-15 Bayer Pharma AG 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas.
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
JP7168552B2 (ja) * 2016-08-18 2022-11-09 ナショナル ユニヴァーシティー オブ シンガポール 造血幹細胞・前駆細胞の作製、増殖および分化のための置換アゾール誘導体
CN109844126A (zh) 2016-09-28 2019-06-04 诺华股份有限公司 基于多孔膜的大分子递送系统
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
EP3609890B1 (en) * 2017-04-12 2024-09-11 EdiGene Biotechnology, Inc. Aryl hydrocarbon receptor antagonists and uses thereof
EP3612030B1 (en) * 2017-04-21 2025-12-24 Ikena Oncology, Inc. Indole ahr inhibitors and uses thereof
AU2018258045B2 (en) 2017-04-26 2024-02-29 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CA3066711A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
JP2020530000A (ja) * 2017-08-02 2020-10-15 ノースウエスタン ユニバーシティ 置換縮合ピリミジン化合物およびその使用
WO2019067792A1 (en) 2017-09-28 2019-04-04 Celularity, Inc. TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY
KR102832035B1 (ko) 2017-09-29 2025-07-09 인텔리아 테라퓨틱스, 인크. 지질 나노파티클을 이용한 mRNA 전달의 체외 방법
US20190343885A1 (en) 2017-10-31 2019-11-14 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
CN111542597A (zh) 2017-10-31 2020-08-14 美真达治疗公司 用于扩增造血干细胞和祖细胞的组合物和方法
WO2019101647A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
CA3082856A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
US11591311B2 (en) 2017-11-21 2023-02-28 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
US11304946B2 (en) 2017-11-21 2022-04-19 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists
AU2018378804B2 (en) 2017-12-06 2025-10-02 Ensoma, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2019136159A1 (en) * 2018-01-03 2019-07-11 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
WO2019156989A1 (en) * 2018-02-06 2019-08-15 Ideaya Biosciences, Inc. COMPOUNDS AND METHODS FOR THE MODULATION OF AhR
US20220340875A1 (en) * 2018-07-19 2022-10-27 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using amido compounds
EP3841102B1 (en) 2018-08-24 2022-09-14 Jaguahr Therapeutics Pte Ltd Tetrahydropyridopyrimidine derivatives as ahr modulators
EP3843853A1 (en) 2018-08-31 2021-07-07 Jaguahr Therapeutics Pte Ltd Heterocyclic compounds as ahr modulators
EA202190654A1 (ru) * 2018-09-07 2021-05-27 Оцука Фармасьютикал Ко., Лтд. Гетероциклическое соединение
EP3849565A4 (en) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
CN113272305A (zh) * 2018-10-16 2021-08-17 医肯纳肿瘤学公司 吲哚ahr抑制剂及其用途
JP2022505615A (ja) * 2018-10-31 2022-01-14 マジェンタ セラピューティクス インコーポレイテッド 造血幹・前駆細胞移植療法の方法
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
CA3150544A1 (en) * 2019-08-12 2021-02-18 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
ES3028099T3 (en) 2019-11-26 2025-06-18 Ikena Oncology Inc Polymorphic carbazole derivatives and uses thereof
TW202134215A (zh) 2019-12-09 2021-09-16 日商大塚製藥股份有限公司 丙烯醯胺化合物
WO2021123920A1 (en) 2019-12-18 2021-06-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ａｈｒシグナル伝達の調節に有用なピリドピリミジン誘導体
WO2021224416A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
CA3177093A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
JP7215776B2 (ja) 2020-07-01 2023-01-31 ネクスジェン株式会社 ヒト長期造血幹細胞マーカー
WO2022029063A1 (en) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
CN114369097B (zh) * 2020-10-15 2023-07-14 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
US20250127809A1 (en) 2021-06-23 2025-04-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
WO2023150393A2 (en) 2022-02-07 2023-08-10 Ensoma, Inc. Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
US12191004B2 (en) 2022-06-27 2025-01-07 Microsoft Technology Licensing, Llc Machine learning system with two encoder towers for semantic matching
WO2024020429A1 (en) 2022-07-22 2024-01-25 Lyell Immunopharma, Inc. Immune cell therapy
JP2025534283A (ja) 2022-10-03 2025-10-15 ジャグエーエイチアール セラピューティクス ピーティーイー リミテッド ＡｈＲシグナル伝達の調節に有用な化合物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399196A (en) 1959-01-22 1968-08-27 Ciba Geigy Corp Nu-substituted pyrazolo-pyrimidines
DE3150486A1 (de) * 1981-12-19 1983-08-25 Merck Patent Gmbh, 6100 Darmstadt Imidazo(4,5-c)pyridine, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5117830A (en) * 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
FR2732604B1 (fr) * 1995-04-07 1997-06-06 Vacsyn Sa Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et compositions les contenant
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1133291B1 (en) 1998-11-17 2006-01-11 Smithkline Beecham Corporation Cyclic polyamines for treating thrombocytopenia
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CZ20012765A3 (cs) 1999-02-01 2002-08-14 Cv Therapeutics, Inc. Purinové inhibitory kinasy 2 a Ikappa - Aalfa dependentní na cyklinu
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
CN1110552C (zh) * 1999-07-13 2003-06-04 中国人民解放军第二军医大学 一种体外扩增造血干细胞的新方法
WO2001017349A1 (en) 1999-09-10 2001-03-15 Smithkline Beckman Corporation Thrombopoietin mimetics
DE60032783T2 (de) 1999-09-24 2007-12-06 Smithkline Beecham Corp. Thrombopoietinmimetika
AU1462201A (en) 1999-11-05 2001-06-06 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
EP1244446B1 (en) 1999-12-06 2006-11-02 SmithKline Beecham Corporation Thrombopoietin mimetics
CA2394646A1 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel purines
WO2001049688A1 (en) * 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP4795618B2 (ja) * 2000-07-18 2011-10-19 ニチモウ株式会社 幹細胞増強素材
WO2002049413A2 (en) 2000-12-19 2002-06-27 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1370252A4 (en) 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
US7176312B2 (en) * 2001-10-12 2007-02-13 The Scripps Research Institute Kinase inhibitor scaffolds and methods for their preparation
KR100948346B1 (ko) * 2001-12-28 2010-03-22 아스비오파마 가부시키가이샤 조혈 줄기 세포 및/또는 조혈 전구 세포의 증식 및/또는분화 촉진제
AU2003248630A1 (en) 2002-06-06 2003-12-22 Smithkline Beecham Corporation Thrombopoietin mimetics
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2004089068A (ja) * 2002-08-30 2004-03-25 Kobe University Ａｈ受容体リガンド特異的な遺伝子発現誘導因子及びその機能に基づく異種遺伝子誘導発現系の利用技術
WO2004054515A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Thrombopoietin mimetics
US20070161582A1 (en) * 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
US20060194782A1 (en) * 2003-09-18 2006-08-31 Altana Pharma Ag Pharmacologically active imidazo[4,5-c] pyridines
MXPA06007095A (es) 2003-12-22 2006-09-04 Gilead Sciences Inc Conjugados de fosfonato inhibidores de cinasa.
EP1724268A4 (en) 2004-02-20 2010-04-21 Kirin Pharma Kk COMPOUNDS WITH TGF-BETA-HEMMENDER EFFECT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
CN101080229A (zh) * 2004-09-03 2007-11-28 普罗米蒂克生物科学公司 免疫调节剂取代的嘌呤基衍生物和其化学保护活性以及其单独使用或与中链脂肪酸或甘油酯联用的用途
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR20070058602A (ko) 2004-09-30 2007-06-08 티보텍 파마슈티칼즈 리미티드 Ｈｃｖ 저해 바이-사이클릭 피리미딘
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
WO2006061380A2 (en) * 2004-12-09 2006-06-15 Altana Pharma Ag SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION
US20060281791A1 (en) * 2005-04-29 2006-12-14 Children's Medical Center Corporation Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
US8153671B2 (en) 2005-07-14 2012-04-10 Irm Llc Heterotetracyclic compounds as TPO mimetics
WO2007022269A2 (en) 2005-08-15 2007-02-22 Irm Llc Compounds and compositions as tpo mimetics
SI2013211T1 (sl) * 2006-04-21 2012-07-31 Novartis Ag Purinski derivati za uporabo kot agonisti receptorja adenozina A A
WO2007145227A1 (ja) 2006-06-14 2007-12-21 Chugai Seiyaku Kabushiki Kaisha 造血幹細胞増加促進剤
WO2007149548A2 (en) * 2006-06-22 2007-12-27 Medistem Laboratories, Inc. Treatment of erectile dysfunction by stem cell therapy
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
WO2008051502A1 (en) 2006-10-19 2008-05-02 Genzyme Corporation Purine derivatives for the treatment of cystic diseases
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
WO2008116911A1 (en) * 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
CA2711759A1 (en) * 2008-01-30 2009-08-06 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity

Also Published As

Publication number Publication date
IL212368A0 (en) 2011-06-30
RS59027B1 (sr) 2019-08-30
EA019872B1 (ru) 2014-06-30
BRPI0921799A2 (pt) 2016-01-12
US9580426B2 (en) 2017-02-28
ECSP11011090A (es) 2011-09-30
HRP20191238T1 (hr) 2019-11-29
CA2943540C (en) 2020-10-27
WO2010059401A3 (en) 2010-09-23
BRPI0921799B1 (pt) 2020-09-29
EP3524604B1 (en) 2023-03-29
ES2736728T3 (es) 2020-01-07
PT2350078T (pt) 2019-07-19
JP5390626B2 (ja) 2014-01-15
JP2012507554A (ja) 2012-03-29
HN2011001195A (es) 2014-01-13
SV2011003888A (es) 2011-07-05
CR20110192A (es) 2011-06-10
EP3524604A1 (en) 2019-08-14
US20170239296A1 (en) 2017-08-24
CO6410309A2 (es) 2012-03-30
EA201100663A1 (ru) 2011-12-30
CA2740589A1 (en) 2010-05-27
BRPI0921799B8 (pt) 2021-05-25
EP2350078B1 (en) 2019-04-17
KR20110075042A (ko) 2011-07-05
CU24495B1 (es) 2021-01-12
MY155137A (en) 2015-09-15
WO2010059401A2 (en) 2010-05-27
CA3061937A1 (en) 2010-05-27
PL2350078T3 (pl) 2019-09-30
US20140114070A1 (en) 2014-04-24
NI201100083A (es) 2011-11-03
CN102203096A (zh) 2011-09-28
US20100183564A1 (en) 2010-07-22
EP2350078A2 (en) 2011-08-03
CA2943540A1 (en) 2010-05-27
MA32828B1 (fr) 2011-11-01
TWI532486B (zh) 2016-05-11
DK2350078T3 (da) 2019-07-15
CY1121857T1 (el) 2020-07-31
GEP20146053B (en) 2014-03-10
SMAP201100024A (it) 2011-07-11
CN102203096B (zh) 2014-09-17
PE20100362A1 (es) 2010-05-27
TW201028153A (en) 2010-08-01
US8927281B2 (en) 2015-01-06
AU2009317898B2 (en) 2013-07-11
ES2948567T3 (es) 2023-09-14
IL212368A (en) 2015-02-26
KR101434719B1 (ko) 2014-08-27
CA2740589C (en) 2017-11-21
US20210187033A1 (en) 2021-06-24
AR074063A1 (es) 2010-12-22
MX347834B (es) 2016-10-07
AU2009317898A1 (en) 2010-05-27
DOP2011000114A (es) 2017-09-29
CU20110096A7 (es) 2012-01-31
CL2013001874A1 (es) 2014-04-04
NZ592435A (en) 2013-01-25
SI2350078T1 (sl) 2019-08-30
JO3593B1 (ar) 2020-07-05
LT2350078T (lt) 2019-07-25
MX2011004593A (es) 2011-06-16
CL2009002010A1 (es) 2010-06-25
TN2011000174A1 (en) 2012-12-17
HUE044802T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
SMP201100024B (it) Composti che espandono cellule staminali ematopoietiche
NO2023019I1 (no) Dupilumab - forlenget SPC
CY2020023I1 (el) Αναστολεiς βητα-λακταμασων
SMT201600377B (it) Angiogenesi utilizzando cellule staminali placentari
EP2785834A4 (en) IMPROVED STEM CELL COMPOSITION
PT2796129E (pt) Composição contendo palmitoiletanolamida ultramicronizada
EP2339910A4 (en) GLASSHOUSE
EP2439313A4 (en) PHOTOELECTROCHEMICAL CELL
FR2957186B1 (fr) Cellule memoire de type sram
DK3412771T3 (da) Amylasepolypeptider
BRPI0918564A2 (pt) inibidores
EP2233803A4 (en) JOINT STRUCTURE
EP2626910A4 (en) PHOTOVOLTAIC CELL
DK3144319T3 (da) Cellekultursammensætning indeholdende laminin-521
EP2207209A4 (en) SOLAR CELL
EP2467882A4 (en) SOLAR CELL
BRPI0909287A2 (pt) Retenção
UY3860Q (es) Reloj
EP2386124A4 (en) SOLAR CELL
EP2273559A4 (en) SOLAR CELL
EP2379884A4 (en) ENERGY CELL
EP2331676A4 (en) GROWTH FACTOR OF A HEMATOPOIETIC STEM CELL
EP2428566A4 (en) GENE TRANSFER AGENT COMPOSITION CONTAINING POLYAMIDOAMINE DENDRIMER
IT1391578B1 (it) Composti carbazolici bistabili
FR2953331B1 (fr) Cellule inorganique photovoltaique